When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and its Cardiovascular Safety.

In this issue of Arthritis and Rheumatology, Giles et al. report much awaited data from the ENTRACTE trial.(1) The United States Food and Drug Administration (FDA)-required this post-marketing randomized controlled trial (RCT) to study the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with monthly tocilizumab (TCZ) 8mg/kg intravenous infusions compared to the risk in those treated with weekly etanercept 50mg subcutaneous injections.(1) This article is protected by copyright. All rights reserved.